Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease.
Sera from patients chronically infected with Trypanosoma cruzi display antibodies that bind to epitopes of living trypomastigotes, known as lytic antibodies (LA), and are detected by a complement-mediated lysis test. Conventional serology antibodies (CSA) are also present in sera from patients with chronic infections but, in contrast to LA, are unable to recognize viable trypomastigotes. The presence of LA has been used as an important element in the criterion of cure in human Chagas' disease. Using flow cytometry technology, we introduced a new and sensitive immunomethod for the detection of anti-live trypomastigote membrane-bound antibodies. On the basis of serological tests (LA and CSA detection) and parasitological assays such as hemoculture (HE), patients were classified into the following groups: chronically infected untreated patients (NT) and treated not-cured patients (TNC), with positive HE and both LA and CSA in their sera; "dissociated" HE-negative patients (DIS), in whom LA was not detected whereas CSA were present; a group of cured HE-negative patients (CUR), who were both LA and CSA negative; and, as control, a group of non-chagasic individuals (NC). Sera from these patients were assayed by incubation with live bloodstream trypomastigotes, which were subsequently exposed to fluorescein isothiocyanate-conjugated anti-human immunoglobulin G. The parasites were then fixed, run in the cytometer, and identified on basis of their size and granularity gain adjustments. On the basis of experience with the complement-mediated lysis test, a level of 20% of parasites being fluorescein isothiocyanate fluorescence positive was used as a cutoff between effective and ineffective treatments. With this criterion, our results indicated that sera from NT and TNC patients were antibody positive whereas all sera from DIS, CUR, and NC patients did not contain membrane-bound antibodies. This new approach is a tool to easily identify anti-live T. cruzi membrane-bound antibodies that can be used to monitor the efficacy of Chagas' disease treatment.
Martins-Filho
O A
OA
Centro de Pesquisas René Rachou, FIOCRUZ, Belo Horizonte, MG, Brazil.
Pereira
M E
ME
Carvalho
J F
JF
Cançado
J R
JR
Brener
Z
Z
D000328:Adult; D000368:Aged; D000818:Animals; D000913:Antibodies, Protozoan / Q000032:analysis* / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology; D014355:Chagas Disease / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D003165:Complement System Proteins / Q000276:immunology; D005434:Flow Cytometry / Q000379:methods; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007113:Immunity, Innate; D008297:Male; D051379:Mice; D008875:Middle Aged; D012698:Serologic Tests / Q000379:methods; D014349:Trypanosoma cruzi / Q000254:growth & development / Q000276:immunology*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D003165:Complement System Proteins